Other
AUR-201
Total Trials
3
Max Phase
—
Type
COMBINATION PRODUCT
Molecule
—
Success Metrics
Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 3 finished
Non-Completion Rate
100.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Terminated(3)
Detailed Status
Terminated3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
terminated3100%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_1
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
NCT06072040
terminatedphase_1
Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201
NCT06078566
terminatedphase_1
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)
NCT06225336
Clinical Trials (3)
Showing 3 of 3 trials
NCT06072040Phase 1
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia
NCT06078566Phase 1
Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201
NCT06225336Phase 1
Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia)
All 3 trials loaded
Drug Details
- Intervention Type
- COMBINATION PRODUCT
- Total Trials
- 3